ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: FR-PO317

Targeting Probiotics in Hyperphosphatemia for Patients with CKD

Session Information

Category: Bone and Mineral Metabolism

  • 501 Bone and Mineral Metabolism: Basic


  • Dissayabutra, Thasinas, Chulalongkorn University, Bangkok, Bangkok, Thailand
  • Anegkamol, Weerapat, Chulalongkorn University, Bangkok, Bangkok, Thailand
  • Chuaypen, Natthaya, Chulalongkorn University, Bangkok, Bangkok, Thailand
  • Taweevisit, Mana, Chulalongkorn University, Bangkok, Bangkok, Thailand
  • Leelahavanichkul, Asada, Chulalongkorn University, Bangkok, Bangkok, Thailand

Group or Team Name

  • Metabolic Diseases in Gastrointestinal and Urologic System Research Unit (MEDGURU).

Hyperphosphatemia and secondary hyperparathyroidism are critical consequences in chronic kidney disease (CKD) patients. Current therapeutic strategies to lower serum phosphate are dietary phosphate restriction and phosphate lowering drugs. Since increased paracellular intestinal phosphate absorption is considered a main factor for hyperphosphatemia, we designed a probiotic cocktail to promote gut barrier, which could subsequently reduce phosphate absorption.


B. longum TCU1 and L. salivarius TCUA were tested in HK2 cell model to be able to promote zonula occluding-1 (ZO-1) expression and had anti-inflammatory effects. The Cocktail A including 109 CFU of B. longum TCU1 and L. salivarius TCUA, inulin and chitosan oligosaccharide (COS), and Cocktail B which was Cocktail 1 added with maltodextrin were used. Cisplatin-induced CKD rats were divided into (a) Control, (b) CKD, (c) CKD with L. casei (commercial probiotic) (d) CKD with Cocktail A and (e) CKD with Cocktail B (n=8 each) were experimented for 12 weeks. Blood was collected to measure calcium (Ca), phosphate (P) and parathyroid hormone (PTH). Immunohistochemistry of intestinal ZO-1 was measured.


All rats with CKD had higher serum creatinine than Control throughout the experiment. AT Week 4 & 8, CKD rats treated with probiotics had lower serum P than CKD rats, while week 12, only CKD rats with Cocktail A had significantly lower serum P than CKD, without serum Ca change. In addition, CLD rats with Cocktail A had lower serum PTH level than CKD rats at week 12. Intestinal ZO-1 expression in Cocktail A rats had non-significantly increased compared to the CKD rats as well.


Our study demonstrated the potential therapeutic effects of targeting probiotic cocktail A, which included B. longum, L. salivarius, inulin and COS, to ameliorate hyperphosphatemia and hyperparathyroidism in rats with CKD. Further study in clinical trial of targeting probiotic had been funded.


  • Government Support – Non-U.S.